.png){kind=icon}
返回
R
Robert Bissonnette
Innovaderm Research
72H指数
470论文数
1.7W被引数
收录论文 255
发表时间
.png){kind=icon}
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials艾克罗金拉通过1年的安全性：用于治疗中重度斑块状银屑病及影响高影响部位银屑病：ICONIC-LEAD、ICONIC-TOTAL和ICONIC-ADVANCE 1和2期3期试验的合并结果.png)
OAAI
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials更正：研究摘要：Delgocitinib乳膏在成人中重度慢性手部湿疹中的疗效与安全性（DELTA 1和DELTA 2）：来自多中心、随机、对照、双盲、III期试验的结果OAAI
OAAI分享收藏Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials研究摘要：Delgocitinib乳膏在患有中重度慢性手部湿疹的成人中的疗效与安全性（DELTA 1和DELTA 2）：来自多中心、随机、对照、双盲、III期试验的结果
OAAI
OAAI分享收藏Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials每日一次口服icotrokinra与安慰剂及每日一次口服deucravacitinib对比，用于中重度斑块状银屑病患者的两项Ⅲ期、随机、安慰剂对照和活性对照药对照试验（ICONIC-ADVANCE 1 & 2）.png)
lancet
lancetIF0
PREAI
分享收藏Response to: “Response to Bissonnette et al. Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy control–matched, phase 4 clinical study (BALISTAD)”回复：“对Bissonnette等人论文的回应：在特应性皮炎成人和青少年患者中，Dupilumab治疗可恢复病灶皮肤和非病灶皮肤的屏障功能，且与filaggrin基因型无关：BALISTAD这项开放标签、健康对照匹配的IV期临床研究的结果”
PREAI
分享收藏